SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings and guidance are the main focus, with traders watching for signs that engagement, subscriber growth and advertising can offset concerns about content quality, recent layoffs and the content leadership change. Views are split between traders bracing for another post-earnings drop and bulls arguing that pessimism is already reflected in the share price.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea is selling off amid trader concerns that its planned Sea Cloud launch and a potential Monee public listing could add uncertainty and spending pressure while Shopee faces subsidy competition from TikTok Shop and Temu. The community is divided over whether the decline is an overreaction to those plans or a sign of deeper competitive and profitability concerns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Some traders cite a new site filing for Sareptas ENHANCE Elevidys safety study, while the broader discussion centers on upcoming DM1/FSHD siRNA readouts and sirolimus safety data. Bulls see these catalysts and possible short covering as reasons for optimism, while skeptics point to weak follow-through and lingering Elevidys and regulatory risks.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospace shares fell despite a quarterly earnings beat and raised outlook, with traders focusing on rising costs, weaker cash conversion, and a loss in its insurance business. The discussion is split between investors viewing the strong demand and orders as a buying opportunity and those frustrated by another sell-the-news reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is centered on anticipation for the full Phase 3 INTerpath-001 melanoma data at ESMO, following positive topline results for its personalized cancer vaccine developed with Merck. Bulls view the detailed readout as potential validation of a broader oncology platform, while bears argue expectations and valuation are stretched and warn of a sell-the-news pullback.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders focused on the cash proceeds and a possible balance-sheet reset. The reaction is divided: bulls view the deal as a strategic catalyst, while skeptics warn that shedding a revenue-generating unit could leave a weaker, debt-burdened business.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rally has sparked breakout and short-squeeze speculation, with traders pointing to bullish chart patterns and the tokens limited supply. Some see it as a catch-up move after prolonged underperformance, while others remain skeptical and want a clearer catalyst; the institutional push and planned V4 are cited as longer-term bullish context.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares fell despite a third-quarter earnings beat and a new buyback authorization, as investors focused on the narrowed full-year profit outlook and unchanged midpoint. Traders are split between buying the dip on stronger cash-flow prospects and the buyback, and worrying that cautious guidance and softer sales point to pressure ahead.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports attention is centered on Phase 2 results for RAP-219 in bipolar mania, which traders say met the primary and secondary endpoints and prompted bullish reactions and analyst upgrades. The response is divided: skeptics question the modest efficacy signal and point to agitation events and higher discontinuations, while shares have shown sharp volatility after the initial enthusiasm.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings report is the main focus, with traders weighing expectations for growth and profitability against concerns about AI-related spending, financing, valuation, and a large post-report share unlock. Some are also speculating about a Tesla merger, but no deal has been announced.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who...

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations PR Newswire NEW YORK, June 17, 2026 Neumora Therapeutics...

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) PR Newswire NEW YORK, June 16...

Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure

NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.

NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials

Equity

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.


Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-neumora-therapeutics-inc-stock...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports...

Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a...

Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)

Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday...

Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday...

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The firm offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. It focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Neumora Therapeutics Inc.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>To conserve cash and refocus resources, Neumora Therapeutics now plans to cut its workforce by about 35%.&nbsp;</li><li>Navacaprant had served as Neumora Therapeutics’ most advanced program.&nbsp;</li><li>Chief Executive Paul Berns said the firm remains “excited about the best-in-class potential” of the updated portfolio despite the setback on its former lead program.</li></ul> Shares of Neumora Therapeutics (NMRA) plunged nearly 47% after the company said that its lead drug candidate, navacaprant, did not outperform placebo in treating major depressive disorder in two late-stage trials.The stock is now on track to clock its worst day since January 2025, if losses hold.<h2 class="st-heading-2">NMRA’s Disappointment Trails</h2>In the KOASTAL-2 and KOASTAL-3 studies, which together enrolled more than 850 adults, patients taking the drug showed similar or slightly smaller improvements in depression symptoms after six weeks compared with those on placebo. Neither trial met its main goal of demonstrating a statistically meaningful benefit.The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant. Navacaprant had served as Neumora Therapeutics’ lead and most advanced program.<h2 class="st-heading-2">Neumora’s Next Steps</h2>To conserve cash and refocus resources, Neumora now plans to cut its workforce by about 35%, generating roughly $10 million in annual savings after one-time costs. It said existing cash provides a runway into the third quarter of 2027.The company highlighted progress in its remaining pipeline, including NMRA-511 for agitation in Alzheimer’s disease, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions. It expects multiple clinical data readouts and study starts over the next 12 months.Chief Executive Paul Berns said the firm remains “excited about the best-in-class potential” of the updated portfolio despite the setback on its former lead program.<h2 class="st-heading-2">How Did NMRA Retail Traders React?</h2>On Stocktwits, retail sentiment around NMRA stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.According to data from Koyfin, seven of the nine analysts covering NMRA rate it ‘Buy’ or higher, while one rates to ‘Hold’ and one ‘Strong Sell.’ The 12-month average price target on the stock is $8.91, representing a potential upside of over 400% from the stock’s last closing price.A Stocktwits user expressed optimism in the company’s remaining pipeline.<stembedurl>https://www.stocktwits.com/Mr_GA/message/656452972</stembedurl>Yet another user opined that the company is “not dead yet.”<stembedurl>https://www.stocktwits.com/Mr_GA/message/656452972</stembedurl>A third user expressed hopes for the company’s experimental drug for obesity, which is slated to enter clinical trials by the end of the year.<stembedurl>https://www.stocktwits.com/Buying_Low_Selling_High/message/656455396</stembedurl><a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> has lost about 42% this year.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-rises-spacex-underwriters-exercise-option/cZKf8h4R73K">SPCX Stock Extends Its Relentless Rally – SpaceX Expands Historic IPO To $85.7B After Underwriters Exercise Greenshoe Option</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$0.4686
Prev Close	$0.47
Open	$0.4793
Dividend Yield	0.00%
50-Day Moving Average	$1.01
Beta	1.42
Avg. Volume	1.7M
PE Ratio	-0.38

52-Week High	$3.65
52-Week Low	$0.3154
Market Capitalization	$88.31M
EPS (Annual)	-$1.45
Price to Book	1.97
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

NMRA Fundamentals